Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Spruce Biosciences (SPRB)
NASDAQ:SPRB
Holding SPRB?
Track your performance easily
SPRB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.41 - $5.95
Previous Close$0.53
Volume171.31K
Average Volume (3M)398.85K
Market Cap
$21.99M
Enterprise Value-$45.14M
Total Cash (Recent Filing)$69.68M
Total Debt (Recent Filing)$2.54M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Mar 12, 2025EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding41,302,599
10 Day Avg. Volume300,226
30 Day Avg. Volume398,851
Standard Deviation0.39
R-Squared0.09
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.37
Price to Sales (P/S)2.30
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-4.72
Enterprise Value/Gross Profit-4.47
Enterprise Value/Ebitda1.06
Forecast
1Y Price Target
$2.33Price Target Upside343.13% Upside
Rating ConsensusHold
Number of Analyst Covering4
Spruce Biosciences News
PremiumCompany Announcements
Spruce Biosciences Reports Q3 2024 Earnings and Updates
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressManagement has reported higher compliance than in the previous trial and patients have good disease control, indicating a chance for positive outcomes in the '204 trial.
Financial PositionSpruce Biosciences ended 2Q24 with $69.7M in cash and cash equivalents, expected to be sufficient to fund operations through the end of 2025 based on the company's current strategic plan.
Market OpportunityTildacerfont could be the second CAH drug to market, tapping into a rare disease market with 20,000 to 30,000 patients in the U.S. and 250 new patients identified annually via newborn screening.
Bears Say
Clinical TrialsTildacerfont showed no effect on A4, attributed to low drug exposure and a hard-to-treat population.
Patient ComplianceCompliance issues, with 50% of patients having less than 80% adherence, could be a reason for the drug's failure in trials.
Regulatory RisksRisks include failure to show clinical impact in the Phase 2b trials of tildacerfont and inability to obtain timely regulatory approval.
---
Ownership Overview
18.30% Insiders
2.75% Mutual Funds
14.12% Other Institutional Investors
62.80% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $0.41 and its highest was $5.95 in the past 12 months.
What is Spruce Biosciences’s market cap?
Currently, no data Available
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is Mar 12, 2025 which is in 109 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on Nov 11, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.238 by $0.028.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -$0.25.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 41,302,600 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.238. Following the earnings report the stock price went down -1.852%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Among the largest hedge funds holding Spruce Biosciences’s share is Aisling Capital Management LP. It holds Spruce Biosciences’s shares valued at N/A.
---
Spruce Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.33 (343.13% Upside)
$2.33 (343.13% Upside)
Blogger Sentiment
Bullish
SPRB Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.33%
12-Months-Change
Fundamentals
Return on Equity
-57.55%
Trailing 12-Months
Asset Growth
-40.05%
Trailing 12-Months
Company Description
Spruce Biosciences
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
---
SPRB Earnings Call
Q4 2024
0:00 / 0:00
---
SPRB Stock 12 Month Forecast
Average Price Target
$2.33
▲(343.13% Upside)
Technical Analysis
Best Analysts Covering SPRB
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-29.70%
reiterated a buy rating 2 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -29.70% per trade.
---